by Truveta staff | Mar 7, 2025 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) in December 2024 were similar to September 2024 (+1.89%). Anti-diabetic medication (ADM) prescribing rates in December 2024 were similar to those in September 2024 (-0.88%). Among ADMs,...
by Truveta staff | Feb 26, 2025 | Research
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of morbidity and mortality. While guideline-directed medical therapy (GDMT) has been shown to improve left ventricular ejection fraction (LVEF), real-world data on LVEF recovery and GDMT...
by Truveta staff | Feb 20, 2025 | Research
Recently, researchers presented new epilepsy research at the American Epilepsy Society Annual Meeting in Los Angeles, California. Using Truveta Data, the researchers explored two important topics: the link between epilepsy, anti-seizure medications, and cardiac...
by Truveta staff | Feb 18, 2025 | Research
Influenza continues to be on the rise. Influenza-related hospitalizations increased by 53.7% and now are associated with 6.8% of all hospitalizations. For kids aged 4 and younger and adults aged 65 and older, the current rate of influenza-related hospitalizations is...
by Truveta Research | Feb 4, 2025 | Research, Research Insights
Mental health prescribing remained relatively stable since 2018. Prescription rates for antidepressants, mood stabilizers, and antipsychotics peaked between 2020 and 2022 but have since stabilized or slightly declined compared to 2018 rates. Anxiolytic prescriptions...
by Truveta staff | Jan 31, 2025 | Research
Discontinuation within one year was significantly higher in patients without T2D (64.8%) compared to those with T2D (46.5%). When patients experienced greater weight loss, they were less likely to discontinue the GLP-1 RA medications. Among patients with T2D, higher...
